by Jean Bedard, CEO, Circulo Pharma
For decades, drug sample management has existed in a regulatory grey zone. It occupies a complex intersection of commercial momentum and clinical intent. For decades, the industry relied on what I call “regulatory goodwill”—managing complex distributions through paper manifests and rep signature sheets. But as someone who has managed over 1,000 GMP and GDP compliance programs across North America and Europe, the era of relying on “good enough” paper trails is ending.
Regulatory guidance has shifted, creating a mandate for total visibility.
Between the 2020 regulatory overhaul, intensified GDP enforcement, and Canada’s pivot toward pharmaceutical serialization1, the compliance bar has shifted from a fixed target to an accelerating one. For third-party logistics (3PL) providers, this isn’t merely a technical hurdle; it is a fundamental strategic imperative. If you cannot provide the level of audit-ready data today’s manufacturers require, you risk more than just an inspection finding; you jeopardize the stability of the client partnership.
The 2020 Baseline: A Shift in Accountability
We must look back at the July 2020 amendments to the Food and Drugs Act to understand our current trajectory. Health Canada did more than just update guidance; they fundamentally redefined the scope of sample distribution for prescription drugs and natural health products alike.
The most consequential change for us in logistics was the directive that sample status is determined by the “totality of facts and circumstances.” This is regulatory shorthand for full chain-of-custody accountability. Health Canada is no longer satisfied with the label on the box; they are scrutinizing the integrity of the entire journey.
Every prescription sample requires a clear, auditable trail from the manufacturer to the specific healthcare professional. Lot-level traceability is no longer optional; it is a fundamental compliance requirement.
Historically, manufacturers carried this burden alone. Today, however, that compliance liability is shared. 3PLs that lack the structural readiness to manage these physical movements with digital precision are leaving their partners—and their own licenses—exposed.
Operational Blind Spots in Modern Logistics
The primary failure point I observe is that many 3PLs try to shoehorn sample distribution into an infrastructure designed for commercial products. This is a strategic error. Legally and operationally, these are different animals.
Commercial distribution creates an invoice, and an invoice creates an automatic trail. In accounting terms, the goods are “seen” by the system.
Samples, by definition, lack that financial trigger. Without a cost associated, the traditional transaction trail disappears. Unless you deliberately build a digital bridge, you are operating in what I call the “post-click blackout.”
From my experience, a compliant operation must address these four critical gaps:
- Granular Traceability vs. Pallet Visibility: A standard Warehouse Management System (WMS) knows where pallets are. But regulators want to know exactly which lot of samples was delivered to which specific clinic. That requires a level of detail that most legacy systems simply aren’t configured to provide.
- Integrated Cold Chain Integrity: In my background with cold chain management, I’ve seen how siloed data creates risk. Excursion logs sitting in a TMS separate from the CRM delivery record create an audit gap. We must link the cold chain record directly to the individual sample record to prove product integrity at the point of distribution.
- HCP Professional Verification: Distributing samples to an unlicensed individual is a catastrophic failure. While verifying licensing may feel like a “sales” function, it is increasingly becoming a logistics gatekeeping requirement. 3PLs must now provide the evidence that these checks occurred before a single unit left the dock.
- Controlled Substance Vigilance: For Schedule I and II drugs, there is zero tolerance for error. Any broken link in the chain of custody directly threatens a manufacturer’s Establishment Licence. For 3PLs, maintaining the chain of custody for controlled substances leaves no room for error.
The Serialization Imperative: Looking Toward 2027
The 2025 pharmacy-readiness milestones have now passed, setting a new baseline for industry capabilities. We are now entering the “Sunrise 2027” era—a global structural shift toward GS1-compliant 2D barcodes. While the US FDA has historically moved faster via DSCSA, Canada’s direction is unambiguous.
The GS1 Canada roadmap established clear expectations for 2D barcode readiness by the end of 2025. In 2026, the focus has broadened to the 2027 global milestone: retail and supply chain POS systems are expected to process GTIN, lot numbers, and expiry data via DataMatrix and QR codes.
At Circulo, we view this infrastructure as the engine of compliant sample management. If you can’t read a DataMatrix code at the point of distribution, you aren’t just behind on technology—you are fundamentally unable to meet the traceability standards of the 2026 pharmaceutical supply chain.
With the GS1 “Sunrise 2027” initiative driving broader adoption, the roadmap encourages manufacturers to apply these same DataMatrix standards to product samples, not just commercial stock. As more manufacturers adopt this approach, 3PLs that cannot process these codes at the point of distribution will face an insurmountable capability gap.
The Reality of GDP Enforcement
I have spent my career ensuring organizations meet Good Distribution Practices (GDP) regulations and guidelines. It is the primary mechanism that makes these requirements real for 3PLs.
Health Canada’s site inspections are active and rigorous. Inadequate sample tracking is a common and avoidable finding that carries significant commercial weight. When a 3PL fails an inspection, it doesn’t just affect their operation; it jeopardizes their client’s ability to stay in the market.
GDP compliance for pharma 3PLs covers the full chain of handling: receipt, storage, temperature control, documentation, distribution, and returns. For drug samples specifically, the documentation requirements are the piece most likely to generate a finding, because they depend on processes that typically exist outside the warehouse — in the manufacturer’s CRM, the rep’s mobile device, or a manual sign-off process that was designed for a world of much lower volume.
As Health Canada’s regulatory modernization continues — the March 2025 amendments to the Food and Drug Regulations touched agile licensing, biologics, and broader supply chain provisions — the expectation is that compliance infrastructure will keep pace. Inspectors are increasingly looking not just at whether records exist, but whether they’re connected, searchable, and retrievable in real time.
Why “Good Enough” is Now a Liability
Five years ago, a mix of spreadsheets and manual delivery calls might have passed an audit. The risk calculus has since shifted. Manual “forensic work” to align logs for an audit is no longer sustainable or acceptable to sophisticated manufacturers.
The risk calculus has shifted. Pharma clients are more exposed than they were, both because Health Canada’s compliance activity has intensified and because the documentation expectations have become more explicit. A 3PL that can’t provide lot-level sample records on request is now a liability, not just an inconvenience — and manufacturers are starting to make sourcing decisions accordingly.
I often ask 3PL leadership: If Health Canada walked in today and asked for the exact location of every unit of a specific lot from the last 12 months, what would you hand them?
If you are scrambling for days to pull that data, you are a liability to your client. In this market, manufacturers are increasingly sourcing partners who can provide that answer in seconds.
The Blueprint for a Compliant 3PL Operation
The good news is that the requirements, while demanding, are manageable if the right systems are in place. A 3PL serving pharma sample clients should be able to demonstrate:
Lot-level receipt and assignment. When samples arrive, each lot is logged with its GTIN, lot number, and expiry — and that record follows the product through to final distribution.
HCP verification at point of order. Before samples ship, the system confirms the recipient is a licensed healthcare professional. This doesn’t have to be a manual process; it can be API-driven against provincial licensing databases or manufacturer-maintained HCP lists.
Cold chain integration. Temperature records are linked to sample records, not stored separately. An auditor looking at a specific lot can see the full cold chain history alongside the distribution record.
Digital proof of delivery. Recipient signature captured electronically, attached to the sample record, timestamped, and stored in a retrievable format.
Exception management. Returns, failed deliveries, and destroyed samples are documented as carefully as successful ones — because the chain of custody has to account for every unit, not just the ones that landed cleanly.
Achieving this does not require a 3PL to become a software developer. It requires a specialized compliance layer sitting between your WMS and your pharma client. At Circulo, we’ve built that bridge—automating the lot-level data, HCP verification, and cold chain linkage that GDP inspectors expect.
The Broader Stakes
Drug sample compliance isn’t just a logistics operations issue. Samples are how new therapies get into the hands of the healthcare professionals who prescribe them — and in a country where many smaller clinics and rural practices depend on samples to trial new medications before committing to formulary, the integrity of that channel matters clinically, not just commercially.
When compliance infrastructure fails, the impact is significant: manufacturers face potential license exposure, while 3PLs risk losing key pharmaceutical partnerships.
In 2026, sophisticated sample management is no longer a competitive differentiator. It is the absolute cost of entry for life sciences logistics.
A Note on Available Solutions
Platforms purpose-built for pharmaceutical sample management — like Circulo — are increasingly filling the gap that exists between legacy WMS systems and the compliance requirements described above. Rather than replacing a 3PL’s existing infrastructure, these tools operate as a compliance layer: capturing the lot-level data, HCP verification, and audit trail that GDP inspectors and pharma clients are asking for. For 3PLs evaluating their sample compliance posture, it’s worth understanding what that category of solution can and can’t do before assuming the answer has to be built from scratch.
For more information, request a demo to see how Circulo can modernize your sample compliance operations, keep you compliant, reduce costs, and reduce your risk.
1 2020 Regulatory Overhaul: Canada Gazette, Part II, Volume 154, Number 9: Regulations Amending the Food and Drug Regulations (Drug Sampling), https://gazette.gc.ca/rp-pr/p2/2020/2020-04-29/html/sor-dors74-eng.html
GDP Enforcement: Health Canada Guidelines for Temperature Control of Drugs during Storage and Transportation (GUI-0069), https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/good-manufacturing-practices/guidance-documents/guidelines-temperature-control-drugs-storage-transportation-0069.html
Pharmaceutical Serialization: GS1 Canada: Healthcare Roadmap, https://gs1ca.org/pharmacy/roadmap/
